This clinical-stage biotech specializing in blood disorders reported a notable insider sale amid strong recent stock ...
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback